Mitoquinone mesylate (MitoQ) is a synthetic analogue of
coenzyme Q10 which has
antioxidant effects. It was first developed in New Zealand in the late 1990s.[1] It has significantly improved bioavailability and improved
mitochondrial penetration compared to coenzyme Q10,[2][3] and has shown potential in a number of medical indications,[4][5][6][7] being widely sold as a
dietary supplement.[8][9]
A 2014 review found insufficient evidence for the use of mitoquinone mesylate in
Parkinson's disease and other movement disorders.[10]
^US abandoned 20060229278, Taylor K, Smith R, "Mitoquinone derivatives used as mitochondrially targeted antioxidants.", published 12 October 2006, assigned to Antipodean Pharmaceuticals Inc
Mitoquinone mesylate (MitoQ) is a synthetic analogue of
coenzyme Q10 which has
antioxidant effects. It was first developed in New Zealand in the late 1990s.[1] It has significantly improved bioavailability and improved
mitochondrial penetration compared to coenzyme Q10,[2][3] and has shown potential in a number of medical indications,[4][5][6][7] being widely sold as a
dietary supplement.[8][9]
A 2014 review found insufficient evidence for the use of mitoquinone mesylate in
Parkinson's disease and other movement disorders.[10]
^US abandoned 20060229278, Taylor K, Smith R, "Mitoquinone derivatives used as mitochondrially targeted antioxidants.", published 12 October 2006, assigned to Antipodean Pharmaceuticals Inc